Description of Invention: This application describes and claims novel pharmocoactive compounds which belong to the class of compounds known as polyketide macrolides. These compounds have been isolated from M. ulcerans, the causative agent of buruli ulcers. Early work with these compounds suggests that the principle compound, mycolactone, or mixtures of mycolactone with other isolated polyketide macrolides or other agents may be useful in treating cancer or suppressing an inflammatory response.
In addition to the novel polyketide macrolide compounds the application also describes compositions derived from a non-virulent strain of M. ulcerans. These compositions may be useful in inducing an immune response (vaccines) which could be useful in providing subjects with resistance to the development of buruli ulcers. Antibodies against mycolactone are being developed. These antibodies could be used for diagnostic purposes.
Inventors: Pamela L Small (NIAID) Kathleen M George (NIAID)
KM George et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999 Feb 5;283(5403):854-857. ( PubMed abs ) [ PubMed abs ]
KM George et al. Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun. 1998 Feb;66(2):587-593. ( PubMed abs ) [ PubMed abs ]
Australian isolates of M. ulcerans [TC Judd et al. Structure determination of mycolactone C via total synthesis. Organic Lett. 2004 Dec 23;6:4901-4904. ( PubMed abs )], as well as [ PubMed abs ]
the frog pathogen M. liflandii [A Mve-Obiang et al. A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin. Infect Immun. 2005 Jun;73(6):3307-3312. ( PubMed abs )]. [ PubMed abs ]
Portfolios: Cancer Cancer - Therapeutics Internal Medicine Internal Medicine - Therapeutics
For Licensing Information Please Contact: Samuel Bish Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: bishse@mail.nih.gov Phone: 301-435-5282 Fax: 301-402-0220
Description of Invention:
This application describes and claims novel pharmocoactive compounds which belong to the class of compounds known as polyketide macrolides. These compounds have been isolated from M. ulcerans, the causative agent of buruli ulcers. Early work with these compounds suggests that the principle compound, mycolactone, or mixtures of mycolactone with other isolated polyketide macrolides or other agents may be useful in treating cancer or suppressing an inflammatory response.
In addition to the novel polyketide macrolide compounds the application also describes compositions derived from a non-virulent strain of M. ulcerans. These compositions may be useful in inducing an immune response (vaccines) which could be useful in providing subjects with resistance to the development of buruli ulcers. Antibodies against mycolactone are being developed. These antibodies could be used for diagnostic purposes.
Inventors:
Pamela L Small (NIAID)
Kathleen M George (NIAID)
Patent Status:
HHS, Reference No. E-199-1999/0
PCT, Application No. PCT/US00/15428 filed 02 Jun 2000
Relevant Publication:
Portfolios:
Cancer
Cancer - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics
For Licensing Information Please Contact:
Samuel Bish Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: bishse@mail.nih.gov
Phone: 301-435-5282
Fax: 301-402-0220
Ref No: 1113
Updated: 02/2011